Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]

ESMO Open. 2022 Jun;7(3):100494. doi: 10.1016/j.esmoop.2022.100494. Epub 2022 Apr 22.
No abstract available

Publication types

  • Published Erratum